Roderick C Slieker, Magnus Münch, Louise A Donnelly, Gerard A Bouland, Iulian Dragan, Dmitry Kuznetsov, Petra J M Elders, Guy A Rutter, Mark Ibberson, Ewan R Pearson, Leen M 't Hart, Mark A van de Wiel, Joline W J Beulens
AIMS/HYPOTHESIS: People with type 2 diabetes are heterogeneous in their disease trajectory, with some progressing more quickly to insulin initiation than others. Although classical biomarkers such as age, HbA1c and diabetes duration are associated with glycaemic progression, it is unclear how well such variables predict insulin initiation or requirement and whether newly identified markers have added predictive value. METHODS: In two prospective cohort studies as part of IMI-RHAPSODY, we investigated whether clinical variables and three types of molecular markers (metabolites, lipids, proteins) can predict time to insulin requirement using different machine learning approaches (lasso, ridge, GRridge, random forest)...
February 19, 2024: Diabetologia